Show simple item record

dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorRuíz-Patiño, Alejandro
dc.contributor.authorZatarain Barrón, Zyanya Lucia
dc.contributor.authorHakim, Fernando
dc.contributor.authorJiménez, Enrique
dc.contributor.authorRamón, Juan Fernando
dc.contributor.authorUseche, Nicolás
dc.contributor.authorBermúdez, Sonia
dc.contributor.authorPineda, Diego
dc.contributor.authorCifuentes, Hernando
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorRicaurte, Luisa
dc.contributor.authorPino, Luis Eduardo
dc.contributor.authorBalaña, Carmen
dc.contributor.authorArrieta, Oscar
dc.contributor.authorMejía Cordovez, Juan Armando
dc.relation.ispartofseriesPlos ONE, 1932-6203, Vol. 14, Nro. 16, 2018, p. 1-13spa
dc.rightsAttribution 4.0 International*
dc.titleSystemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinibspa
dc.subject.decsNeoplasias de tejido nerviosospa
dc.subject.decsCompuestos orgánicosspa
dc.subject.decsConformación molecularspa
dc.publisher.journalPlos ONEspa
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidRuíz-Patiño, Alejandro [0000-0003-1274-9273]
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame: Repositorio Institucional Universidad El Bosquespa
dc.description.abstractenglishPurpose To compare the effectiveness of octreotide/everolimus vs. sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRβ and VEGFR2, their expression was correlated with outcomes. Results Twenty-two patients (72%) were female with a median age of 55 years (SD±15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octreotide/everolimus, 11 received sunitinib and the remaining 6 received other second-line agents. Median OS was 37.3 months (95%CI 28.5–42.1) and the PFS during the treatment with everolimus/octreotide (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2–21.1) and 9.1 months (95%CI 6.8–16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence (36.0 vs. 29.5 months) (p = 0.0001). When analyzing molecular markers, the positive PDGFRβ and negative VEGFR2 expression were associated with longer survival both in OS and PFS. Conclusion Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better
dc.rights.localAcceso abiertospa

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International